While lithium orotate is capable of providing lithium to the body, like lithium carbonate and other lithium salts, there are no systematic reviews supporting the efficacy of lithium orotate and it is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition.
In 1973, Nieper reported that lithium orotate contained 3.83 mg of elemental lithium per 100 mg and lithium carbonate contained 18.8 mg of elemental lithium per 100 mg Nieper went on to claim that lithium did not dissolve from the orotate carrier until it passed through the blood brain barrier, however a 1976 study documented that lithium concentrations within the brains of rats were not statistically different between equivalent dosages of lithium from lithium orotate, lithium carbonate, or lithium chloride. While this study was conducted with rats, it directly contradicts the aforementioned assumptions made by Nieper and others. The pharmacokinetics of lithium orotate in human brains is poorly documented and further inquiry is needed to affirm that lithium concentrations in the brain are higher with lithium orotate. Major medical research has not been conducted on lithium orotate since the 1980s due to its patent status and the abundant availability of lithium carbonate. As previously stated, lithium intake appears to be effective even at low doses, and this may account for lithium orotates claimed effectiveness.
A 1979 study states. "The renal lithium clearance was significantly lower, the kidney weight and the lithium concentrations in serum, kidney and heart significantly higher after injection of lithium orotate than after injection of lithium carbonate". However, that same study also concluded, "This data suggest the possibility that lower doses of lithium orotate than lithium carbonate may achieve therapeutic brain lithium concentrations and relatively stable serum concentrations."
Orotic acid can be mutagenic in mammalian somatic cells. It is also mutagenic for bacteria and yeast.
^Alevizos B, Alevizos E, Leonardou A, Zervas I (2012). "Low dosage lithium augmentation in venlafaxine resistant depression: An open-label study". Psychiatrike.23 (2): 143–8. PMID22796912.
^Nunes MA, Viel TA, Buck HS I (2013). "Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease". Curr Alzheimer Res.10 (1): 104–7. doi:10.2174/156720513804871354. PMID22746245.
^Berger GE, Wood SJ, Ross M, Hamer CA, Wellard RM, Pell G, Phillips L, Nelson B, Amminger GP, Yung AR, Jackson G, Velakoulis D, Pantelis C, Manji H,McGorry PD I (2012). "Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study". Curr Pharm Des.18 (4): 570–5. doi:10.2174/138161212799316163. PMID22239590.